$BHVN News
Last published 1w ago
- 1w agoBHVNBiohaven Ltd. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoBHVNBiohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsPR NewswireThe US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global license with SK
- 2w agoBHVNBiohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous NephropathyPR NewswireOne year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing
- 1mo agoBHVNTYO:4528Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseasePR NewswireOno will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation
- 1mo agoBHVNBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026PR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 2mo agoBHVNBiohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for EpilepsyPR NewswireBiohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and SK Biopharmaceuticals Co., Ltd. ("SK Biopharmaceuticals") today...
- 2mo agoBHVNFederal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale UniversityPR NewswireBiohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District...
- 3mo agoBHVNFederal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 MillionPR NewswireBiohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the...
- 3mo agoBHVNBiohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) PayloadPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 4mo agoBHVNBiohaven Announces Scientific Leadership TransitionsPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug...
- 4mo agoBHVNBiohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 ActivatorPR NewswireBiohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
- 4mo agoBHVNBiohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' DiseasePR NewswireBiohaven Ltd. (NYSE: BHVN) today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is...
- 5mo agoBHVNBiohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and ImmunomodulationPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
- 5mo agoBHVNBiohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA NephropathyPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
- 5mo agoBHVNBiohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability ProfilePR NewswireBiohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
- 6mo agoBHVNBiohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 7mo agoBHVNBiohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
- 8mo agoBHVNBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial ResultsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 10mo agoBHVNBiohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
- 10mo agoBHVNBiohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026PR NewswireBiohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan...
- 10mo agoBHVNBiohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive DisorderPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
- 11mo agoBHVNBiohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology CongressPR NewswireBiohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical...
- 12mo agoBHVNBiohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200MPR NewswireBiohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
- 12mo agoBHVNBiohaven Announces Pricing of $175 Million Public Offering of Common SharesPR NewswireBiohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
- 1y agoBHVNBiohaven Announces Proposed Public Offering of Common SharesPR NewswireBiohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
- 1y agoBHVNBiohaven Reports Third Quarter 2025 Financial Results and Recent Business DevelopmentsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 1y agoBHVNFDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar AtaxiaPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 1y agoBHVNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVNGlobeNewswireNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE:BHVN). Shareholders who purchased shares of BHVN during the class period listed are
- 1y agoBHVNINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ("Biohaven" or the "Company")...
- 1y agoBHVNSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoBHVNSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ("Biohaven" or the "Company")...
- 1y agoBHVNShareholders of Biohaven Ltd. Should Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights – BHVNGlobeNewswireNEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE:BHVN). Shareholders who purchased shares of BHVN during the class period listed are
- 1y agoBHVNBHVN Investors Have the Opportunity to Lead the Biohaven Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoBHVNBiohaven Ltd. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BHVNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the...
- 1y agoBHVNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVNGlobeNewswireNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE:BHVN). Shareholders who purchased shares of BHVN during the class period listed are
- 1y agoBHVNBiohaven Reports Second Quarter 2025 Financial Results and Recent Business DevelopmentsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 1y agoBHVNBiohaven Ltd. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights - BHVNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the...
- 1y agoBHVNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the...
- 1y agoBHVNSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoBHVNInvestors in Biohaven Ltd. Should Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights – BHVNGlobeNewswireNEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE:BHVN). Shareholders who purchased shares of BHVN during the class period listed are
- 1y agoBHVNINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ("Biohaven" or the "Company")...
- 1y agoBHVNINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoBHVNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVNGlobeNewswireNEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE:BHVN). Shareholders who purchased shares of BHVN during the class period listed are
- 1y agoBHVNShareholders of Biohaven Ltd. Should Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights - BHVNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the...
- 1y agoBHVNBexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug DevelopmentGlobeNewswireNEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a
- 1y agoBHVNBiohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 InhibitorPR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
- 1y agoBHVNBiohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)PR NewswireBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
- 1y agoBHVNBiohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of TumorsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
- 1y agoBHVNFDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar AtaxiaPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed...
- 1y agoBHVNBiohaven Reports First Quarter 2025 Financial Results and Recent Business DevelopmentsPR NewswireBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...